Fennec Pharmaceuticals Inc.
FENC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $12,462 | $9,652 | $8,751 | $7,925 |
| % Growth | 29.1% | 10.3% | 10.4% | – |
| Cost of Goods Sold | $660 | $967 | $373 | $669 |
| Gross Profit | $11,802 | $8,685 | $8,378 | $7,256 |
| % Margin | 94.7% | 90% | 95.7% | 91.6% |
| R&D Expenses | $29 | $107 | $94 | $50 |
| G&A Expenses | $6,752 | $6,956 | $6,145 | $4,196 |
| SG&A Expenses | $11,962 | $11,310 | $9,092 | $8,140 |
| Sales & Mktg Exp. | $5,210 | $4,354 | $2,947 | $3,944 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $11,991 | $11,417 | $9,186 | $8,190 |
| Operating Income | -$189 | -$2,732 | -$808 | -$934 |
| % Margin | -1.5% | -28.3% | -9.2% | -11.8% |
| Other Income/Exp. Net | -$449 | -$420 | -$357 | -$686 |
| Pre-Tax Income | -$638 | -$3,152 | -$1,165 | -$1,620 |
| Tax Expense | $0 | $0 | $0 | $365 |
| Net Income | -$638 | -$3,152 | -$1,165 | -$1,985 |
| % Margin | -5.1% | -32.7% | -13.3% | -25% |
| EPS | -0.02 | -0.12 | -0.042 | -0.072 |
| % Growth | 83.3% | -184.4% | 41.6% | – |
| EPS Diluted | -0.02 | -0.12 | -0.042 | -0.057 |
| Weighted Avg Shares Out | 27,889 | 27,664 | 27,578 | 27,460 |
| Weighted Avg Shares Out Dil | 27,889 | 27,664 | 27,578 | 27,460 |
| Supplemental Information | – | – | – | – |
| Interest Income | $152 | $174 | $235 | $374 |
| Interest Expense | $586 | $617 | $603 | $966 |
| Depreciation & Amortization | $51 | $25 | $26 | $25 |
| EBITDA | -$1 | -$2,533 | -$782 | -$909 |
| % Margin | -0% | -26.2% | -8.9% | -11.5% |